Addimmune

Executive Summary

Addimmune, a project within American Gene Technologies (AGT), is advancing a gene and cell therapy aimed at providing a functional cure for HIV. The approach involves engineering a patient's own cells to resist HIV infection, potentially enabling durable remission with a single treatment. By targeting the root cause of HIV persistence, Addimmune's therapy could eliminate the need for lifelong antiretroviral therapy for people living with HIV (PLHIV). The company is based in Philadelphia and was founded in 2016, operating in the RNA and gene therapy space. While still in early development, Addimmune's unique strategy—leveraging lentiviral vectors to deliver anti-HIV genes—differentiates it from other curative approaches like broadly neutralizing antibodies or latency-reversing agents. The project benefits from AGT's established platform and expertise in gene therapy, though specific financial details and clinical milestones remain undisclosed. If successful, Addimmune could transform the lives of millions of PLHIV globally, offering a one-time cure that reduces stigma, healthcare costs, and viral transmission.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Phase I Clinical Trial70% success
• Q2 2026Preclinical Efficacy Data Publication80% success
• TBDPartnership or Funding Announcement50% success